Loading clinical trials...

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies

NCT04772989•Arcus Biosciences, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
•Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
•Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
•Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
•Adequate organ and marrow function

Exclusion Criteria

•History of trauma or major surgery within 28 days prior to the first dose of study treatment.
•Prior treatment with an anti-TIGIT antibody.
•Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
•Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
•Discontinued prior immunotherapy for immune related adverse events with a high severity.

Locations (22)

UCLA Department of Medicine - Hematology/Oncology

Los Angeles, California, United States

Mayo Clinic Jacksonville - PPDS

Jacksonville, Florida, United States

Goshen Health System

Goshen, Indiana, United States

Holden Comprehensive Cancer Center

Iowa City, Iowa, United States

Norton Cancer Insititute-Downtown

Louisville, Kentucky, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Columbia University Medical Center

New York, New York, United States

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

University of Oklahoma Peggy and Charles Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Key Dates

Start Date

March 19, 2021

Primary Completion Date

August 25, 2025

Completion Date

August 25, 2025

Last Updated

August 28, 2025

Enrollment

ACTUAL participants

Conditions

Advanced Solid TumorNon Small Cell Lung Cancer (NSCLC)MelanomaCervical CancerMultiple MyelomaLymphoma, Non-HodgkinDiffuse Large B Cell Lymphoma (DLBCL)Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer

Interventions

AB308

DRUG

Zimberelimab

DRUG

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

RECRUITINGPHASE1

A Study of PYX-201 in Advanced Solid Tumors

NCT05720117

Solid TumorAdvanced Solid Tumor

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 28, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Inclusion Criteria

Exclusion Criteria

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

A Study of PYX-201 in Advanced Solid Tumors

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer